Scientists Find Blood Clue That May Predict Who Survives Common Cancer
Summary
Scientists studied changes in white blood cells from melanoma patients to see how these cells respond to immunotherapy. Their findings suggest that certain immune cell patterns in the blood might help predict who benefits from treatment and who may face worse outcomes.Key Facts
- The study focused on melanoma, a serious skin cancer that is common in the U.K. and the U.S.
- Researchers examined B cells (which produce antibodies) and T cells (which attack cancer cells) from patients' blood.
- Patients with active and growing B and T cells during the first six weeks of treatment tended to survive longer.
- Patients whose B cells were immature or weak during treatment had poorer survival rates.
- Some T cell types were linked to side effects from immunotherapy.
- The study involved 24 melanoma patients and 25 healthy volunteers.
- Scientists used mass cytometry, a technology that measures many features of individual immune cells at once.
- This research may help doctors use blood tests to better decide on melanoma treatment plans in the future.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
